According to the Vision Research Reports, the global macular degeneration treatment market size is expected to reach US$ 11.5 billion by 2027 and projected to expand at a CAGR of 6.7% from 2020 to 2027.
The report offers detailed segmentation of the global macular degeneration treatment market based on disease indication, drug class, and distribution channel. The market has also been segregated based on region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The Anti-VEGF therapies segment is likely to drive the global market. Key players are tapping opportunities to introduce therapies for geographic atrophy, which are expected to boost the number of treated geographic atrophy cases, thereby drive the macular degeneration treatment market. Research and development of groundbreaking drugs could increase, as several patents stand on the brink of expiry. Consequently, enrolment in clinical trials is expected to rise in the near future. Companies are likely to ink licensing agreements and forge tactical collaborations to strengthen their position in the market. They are anticipated to back their blockbuster drugs in order to win over their rivalry with other players. Bayer, Regeneron, Roche/Genentech, and Novartis AG are some companies that could make their presence known in the market.
Technical advancements and promising pipeline products assure improved growth
Growing prevalence of AMD is expected to boost the global market, while this could be an obvious growth factor of the market, there are other factors that are expected to propel the market in the near future. For instance, increase in healthcare expenditure and patient awareness are expected to boost the market. Moreover, introduction of advanced medications in AMD is also projected to propel the market.
Launch of novel products for the treatment of geographic atrophy, late stage of dry age-related macular degeneration treatment (dAMD), and wet AMD (wAMD) are key drivers of the AMD market. Drugs such as Apellis’ APL-2, Ophthotech’s Zimura and Novartis’ longer-acting anti-VEGF, brolucizumab are estimated to fuel the global macular degeneration treatment market. In particular, the launch of drugs into the AMD market to treat dAMD is anticipated to be a major factor, as currently, no prescription medications are available for these patients.
Brands with drug patents accused of extortionately pricing high demand products
Patent expiry is likely to pose a threat to the expansion of market players. On the other hand, exorbitant pricing may not be a good strategy to adopt for players who possess patents for their drugs. For instance, patent expire of Lucentis during the forecast period. Several companies are in the race to introduce Lucentis biosimilar for monthly treatment of neovascular age-related macular degeneration treatment (nAMD), with plans to bring introduce it into the market during the forecast period, such as Samsung Bioepis, SB11 and bioeq, FYB201. Moreover, a lack of prescription drugs in the international AMD market is expected to hamper demand in the near future.
Specialty clinics segment to expand at rapid pace
The hospitals segment accounted for a significant share of the global market, followed by the ophthalmic clinics segment, in 2019. The ophthalmic clinics segment is anticipated to expand at a high CAGR during the forecast period. Affordable health care facilities provided in specialty clinics is a major factor fueling the segment. Ophthalmic clinics is the second-leading segment, as the primary detection and treatment of AMD are carried out at hospitals. The ambulatory surgical centers segment accounted for a relatively minor share of the market. It is expected to expand at a steady pace during the forecast period.
Market in North America to register exponential growth
In terms of revenue, the macular degeneration treatment market in North America is projected to expand at a CAGR of 7.2% during the forecast period. North America dominated the global macular degeneration treatment market, in terms of revenue, in 2017. It is projected to maintain its dominant position during the forecast period. High rate of adoption of prescription AMD drugs in the U.S. and increasing number of approvals for new drugs from the U.S. FDA are major factors responsible for the high share held by North America in 2019.
The report analyzes and forecasts the macular degeneration treatment market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of macular degeneration treatment, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major macular degeneration treatment companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of macular degeneration treatment upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of macular degeneration treatment and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global macular degeneration treatment market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the macular degeneration treatment market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of macular degeneration treatment market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in the Report
The report profiles major players operating in the global macular degeneration treatment market in terms of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in this report include Allergan, Inc., Pfizer, Inc., Novartis AG., REGENERON PHARMACEUTICALS, INC., Santen Pharmaceuticals, Valeant Pharmaceuticals, F. Hoffmann-La Roche Ltd., Sanofi, and Bayer AG.
The global macular degeneration treatment market has been segmented as follows:
By Disease Indication
By Drug Class
By Distribution Channel
By Region
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Macular Degeneration Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Indication Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. Growing prevalence of AMD owing to increase in the geriatric population
4.3.1.2. Increase in health care spending and improvement in health care infrastructure
4.3.1.3. New product launches and high annual cost of therapy (ACOT)
4.3.1.4. Rise in number of eye care centers leading to increased product utilization
4.3.2. Restraints
4.3.2.1. Patent expiry of three well-established anti-VEGFs
4.3.2.2. Non-compliance with treatment
4.3.2.3. Lack of awareness
4.3.3. Opportunities
4.4. Global Macular Degeneration Treatment Market Analysis and Forecast, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insight
5.1. Regulatory Scenario by Region/Globally
5.2. Key Mergers & Acquisitions
5.3. AMD Clinical Trial Analysis
5.4. Reimbursement Scenario
5.5. AMD Prevalence Rate Globally with Key Countries
6. Global Macular Degeneration Treatment Market Analysis and Forecast, by Disease Indication
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
6.3.1. Wet age-related macular degeneration
6.3.2. Dry age-related macular degeneration
6.3.3. Others
6.4. Global Macular Degeneration Treatment Market Attractiveness, by Disease Indication
7. Global Macular Degeneration Treatment Market Analysis and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
7.3.1. Anti-vascular endothelial growth factor
7.3.2. Others
7.4. Global Macular Degeneration Treatment Market Attractiveness, by Drug Class
8. Global Macular Degeneration Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
8.3.1. Hospitals
8.3.2. Ophthalmic Clinics
8.3.3. Ambulatory Surgical Centers
8.4. Global Macular Degeneration Treatment Market Attractiveness, by Distribution Channel
9. Global Macular Degeneration Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Macular Degeneration Treatment Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Macular Degeneration Treatment Market Attractiveness, by Region
10. North America Macular Degeneration Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
10.2.1. Wet age-related macular degeneration
10.2.2. Dry age-related macular degeneration
10.2.3. Others
10.3. North America Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
10.3.1. Anti-vascular endothelial growth factor
10.3.2. Others
10.4. North America Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospitals
10.4.2. Ophthalmic Clinics
10.4.3. Ambulatory Surgical Centers
10.5. North America Macular Degeneration Treatment Market Value Forecast, by Country, 2016–2026
10.5.1. U.S.
10.5.2. Canada
10.6. North America Macular Degeneration Treatment Market Attractiveness Analysis
10.6.1. By Disease Indication
10.6.2. By Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Macular Degeneration Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
11.2.1. Wet age-related macular degeneration
11.2.2. Dry age-related macular degeneration
11.2.3. Others
11.3. Europe Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
11.3.1. Anti-vascular endothelial growth factor
11.3.2. Others
11.4. Europe Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospitals
11.4.2. Ophthalmic Clinics
11.4.3. Ambulatory Surgical Centers
11.5. Europe Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Macular Degeneration Treatment Market Attractiveness Analysis
11.6.1. By Disease Indication
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Macular Degeneration Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
12.2.1. Wet age-related macular degeneration
12.2.2. Dry age-related macular degeneration
12.2.3. Others
12.3. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
12.3.1. Anti-vascular endothelial growth factor
12.3.2. Others
12.4. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospitals
12.4.2. Ophthalmic Clinics
12.4.3. Ambulatory Surgical Centers
12.5. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016–2026
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Macular Degeneration Treatment Market Attractiveness Analysis
12.6.1. By Disease Indication
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Macular Degeneration Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
13.2.1. Wet age-related macular degeneration
13.2.2. Dry age-related macular degeneration
13.2.3. Others
13.3. Latin America Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
13.3.1. Anti-vascular endothelial growth factor
13.3.2. Others
13.4. Latin America Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospitals
13.4.2. Ophthalmic Clinics
13.4.3. Ambulatory Surgical Centers
13.5. Latin America Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Macular Degeneration Treatment Market Attractiveness Analysis
13.6.1. By Disease Indication
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Macular Degeneration Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
14.2.1. Wet age-related macular degeneration
14.2.2. Dry age-related macular degeneration
14.2.3. Others
14.3. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
14.3.1. Anti-vascular endothelial growth factor
14.3.2. Others
14.4. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
14.4.1. Hospitals
14.4.2. Ophthalmic Clinics
14.4.3. Ambulatory Surgical Centers
14.5. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016–2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis
14.6.1. By Disease Indication
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Market Share Analysis by Company & Competition Matrix (By Tier and Size of companies)
15.2. Company Profiles
15.2.1. Allergan plc.
15.2.1.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.1.2. Business Overview
15.2.1.3. Product Portfolio
15.2.1.4. Financial Overview
15.2.1.5. SWOT Analysis
15.2.2. Novartis AG
15.2.2.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.2.2. Business Overview
15.2.2.3. Product Portfolio
15.2.2.4. Financial Overview
15.2.2.5. SWOT Analysis
15.2.3. Pfizer Inc.
15.2.3.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.3.2. Business Overview
15.2.3.3. Product Portfolio
15.2.3.4. Financial Overview
15.2.3.5. SWOT Analysis
15.2.4. Santen Pharmaceuticals Co. Ltd.
15.2.4.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.4.2. Business Overview
15.2.4.3. Product Portfolio
15.2.4.4. Financial Overview
15.2.4.5. SWOT Analysis
15.2.5. Valeant Pharmaceuticals International, Inc.
15.2.5.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.5.2. Business Overview
15.2.5.3. Product Portfolio
15.2.5.4. Financial Overview
15.2.5.5. SWOT Analysis
15.2.6. Bayer AG
15.2.6.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.6.2. Business Overview
15.2.6.3. Product Portfolio
15.2.6.4. Financial Overview
15.2.6.5. SWOT Analysis
15.2.7. F. Hoffmann-La Roche Ltd.
15.2.7.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.7.2. Business Overview
15.2.7.3. Product Portfolio
15.2.7.4. Financial Overview
15.2.7.5. SWOT Analysis
15.2.8. Sanofi
15.2.8.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.8.2. Business Overview
15.2.8.3. Product Portfolio
15.2.8.4. Financial Overview
15.2.8.5. SWOT Analysis
15.2.9. REGENERON PHARMACEUTICALS, INC.
15.2.9.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.9.2. Business Overview
15.2.9.3. Product Portfolio
15.2.9.4. Financial Overview
15.2.9.5. SWOT Analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers